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Abstract
Objective: Stress and glucocorticoid hormones, which are released into the circulation following stressful experiences, have
been shown to contribute significantly to the manifestation of anxiety-like behaviors observed in many neuropsychiatric
disorders. Brain-derived neurotrophic factor (BDNF) signaling through its receptor TrkB plays an important role in stress-
mediated changes in structural as well as functional neuroplasticity. Studies designed to elucidate the mechanisms whereby
TrkB signaling is regulated in chronic stress might provide valuable information for the development of new therapeutic
strategies for several stress-related psychiatric disorders.
Materials and Methods: We examined the potential of cysteamine, a neuroprotective compound to attenuate anxiety and
depression like behaviors in a mouse model of anxiety/depression induced by chronic corticosterone exposure.
Results: Cysteamine administration (150 mg/kg/day, through drinking water) for 21 days significantly ameliorated chronic
corticosterone-induced decreases in TrkB protein levels in frontal cortex and hippocampus. Furthermore, cysteamine
treatment reversed the anxiety and depression like behavioral abnormalities induced by chronic corticosterone treatment.
Finally, mice deficient in TrkB, showed a reduced response to cysteamine in behavioral tests, suggesting that TrkB signaling
plays an important role in the antidepressant effects of cysteamine.
Conclusions: The animal studies described here highlight the potential use of cysteamine as a novel therapeutic strategy for
glucocorticoid-related symptoms of psychiatric disorders.
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Introduction
Chronic stress and elevated levels of glucocorticoids have been
implicated in psychiatric disorders including anxiety, depression
and schizophrenia [1]. In addition, chronic exposure to glucocor-
ticoids has been shown to manifest anxiety like symptoms in
rodents [2]. Brain derived neurotrophic factor (BDNF) signal-
ing through its receptor TrkB plays an important role in
neuroplasticity [3–5], and chronic stress has been known to
result in alterations in BDNF/TrkB signaling and changes in
neuronal functions [6–7]. Moreover, human postmortem studies
have revealed changes in TrkB mRNA and protein levels in
schizophrenia [8] and suicide subjects [9]. The argument that
TrkB signaling plays an important role in anxiety and depression
has been further strengthened by a recent study which indicated
that mice lacking TrkB exhibit increased anxiety-like behaviors
[10].
Many studies have shown that the prevalence of anxiety
symptoms in schizophrenia and depression patients is higher than
in the general population indicating the importance of developing
new treatment strategies for this aspect of the disorders [11–12].
Cysteamine, the FDA-approved drug currently prescribed for
cystinosis, has anti-oxidant properties [13]. Evidence also indicates
that short-term treatment of mice with cysteamine increases brain
as well as serum BDNF levels in rodents [14–15]. A recent study
from our laboratory has shown that cysteamine increases TrkB
signaling in mouse frontal cortex [15].
In the present study, we evaluated the potential of cysteamine to
attenuate chronic corticosterone-induced changes in TrkB protein
levels and anxiety/depression-like behaviors in mice. Furthermore,
the possible role of TrkB in mediating cysteamine effects was
examined using TrkB knockout mice.
Results
Each mouse typically ingested approximately 6 ml of water per
day (24 h) and gained approximately 10 g over the course of the
study. However, no significant difference in relative body weight
gain during the experiment or water intake was found between
any of the treatment groups (data not shown)
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protein levels in mouse frontal cortex and hippocampus
The expression of the BDNF receptor, TrkB was examined in
frontal cortex and hippocampus after 3, 5 and 7 weeks of
corticosterone treatment. In the frontal cortex, two-way ANOVA
revealed a significant main effect of treatment [F(1,25)=6.063;
p=0.02] and a significant treatment x time interaction
[F(2,25)=3.304; p=0.05], without a significant effect of time
[F(2,25)=1.639; p=0.214]. Post hoc analysis indicated that
treatment with corticosterone for 3 (Fig 2A) and 5 (Fig 2B) weeks
didnot changeTrkBproteinlevels,but7-weektreatmentresultedin
a significant decrease in TrkB protein levels (Fig 2C; p,0.05). In
hippocampus, there was a significant main effect of time
[F(2,24)=16.07; p,0.0001] and treatment [F(1,24)=34.63;
p,0.0001],without a significant treatment x time interaction
[F(2,24)=1.295; p=0.292]. Interestingly, TrkB protein levels in
thehippocampusweresignificantlydecreasedingroupstreatedwith
corticosterone for 3 (Fig 3A;p,0.01), 5 (Fig 3B; p,0.01) and 7
(Fig 3C; p,0.05) weeks. We also examined the protein levels of
truncated TrkB in the above brain areas following corticosterone
treatment; however, we did not find any change in truncated TrkB
levelsinany ofthetreatmentgroups(datanot shown).Todetermine
whether TrkB downregulation occurred at the mRNA level, we
examined TrkB mRNA expression in the frontal cortex and
hippocampus from the 7-week corticosterone treated mice. TrkB
mRNA levels in corticosterone-treated mice did not differ from
vehicle-treated mice (Fig 4).
Cysteamine attenuates chronic corticosterone-induced
decrease in TrkB protein levels
Subsequently, we determined if cysteamine could reverse
corticosterone-induced decreases in TrkB protein levels. CD-1
mice were treated for 7 weeks with vehicle or corticosterone in the
presence or absence of cysteamine during the last three weeks of
Figure 1. Experimental designs used for testing the behavioral and biochemical responses to cysteamine treatment in CD-1 and
TrkB knockout mice. (1) CD-1 male mice were treated for 7 weeks with corticosterone (CORT; 35 ug/ml/day) or vehicle (0.45% hydroxypropyl-b-
cyclodextrin) in presence or absence of cysteamine (150 mg/kg) during the last three weeks of corticosterone or vehicle treatment. At the end of the
treatment, the same animal was successively tested in the Open Field (OF) paradigm, the Light/dark test, the Elevated Plus Maze test (EPM), the Tail
Suspension Test (TST) and then sacrificed for protein or mRNA analysis. (2) Cysteamine (150 mg/kg) or water (vehicle) was administered through
drinking water to TrkB knockout and wild type mice for 21 days. At the end of the treatment, mice were killed and brains removed for behavioral and
biochemical analyses.
doi:10.1371/journal.pone.0026153.g001
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with corticosterone/vehicle pretreatment and cysteamine/vehicle
as main effects indicated significant main effect of pretreatment
[(F(1,18)=34.69; p,0.0001] and treatment [F(1,18)=26.81;
p,0.0001], but without a significant pretreatment x treatment
interaction [F(1,18)=0.3669; p=0.552]. Post hoc analysis with
Bonferroni’s multiple comparison test showed that treatment with
cysteamine significantly increased TrkB protein levels in frontal
cortex (Fig 5A). The increase in TrkB protein levels was observed in
both corticosterone (p,0.001) and non-corticosterone treated
animals (p,0.05). Similar to frontal cortex, data from hippocampus
showed significant main effect of pretreatment [F(1,18)=40.84;
P,0.0001] and treatment [F(1,18)=88.46; p,0.0001]. No signif-
icant effect was found in pretreatment x treatment interaction in
hippocampus [F(1,18)=2.729; p=0.118]. The reduction in TrkB
proteinlevelsinthehippocampusinducedbychroniccorticosterone
was reversed by cysteamine (Fig 5B; p,0.05). We did not find any
significant change in truncated TrkB levels following cysteamine
treatment in the vehicle or corticosterone treated groups (data not
shown). Taken together, these results suggest that chronic
cysteamine treatment is effective in reversing the reductions in
TrkB protein levels induced by excess glucocorticoids.
Cysteamine treatment did not change BDNF and plasma
corticosterone levels
We also determined whether treatment with corticosterone
and/or cysteamine in mice alters BDNF levels in frontal cortex
and hippocampus. We measured BDNF protein levels using
western blots instead of routine ELISA methods to determine the
difference in proBDNF and mature BDNF protein levels. Two-
way ANOVA on proBDNF levels in the frontal cortex did not find
any significant main effect of pretreatment [F(1,18)=0.0604;
p=0.808], treatment [F(1,18)=1.4; p=0.253] and pretreatment x
treatment interaction [F(1,18)=0.219; p=0.645]. Similarly, the
data on mature BDNF levels in frontal cortex did not yield
significant main effect of pretreatment [F(1,18)=0.0062;
p=0.938], treatment [F(1,18)=1.05; p=0.318] and pretreatment
x treatment interaction [F(1,18)=0.0165; p=0.899]. Two-way
ANOVA revealed a significant main effect of treatment
[F(1,18)=5.77; p,0.01] on proBDNF levels in hippocampus,
but no effect of pretreatment [F(1,18)=1.709; p=0.208] and
pretreatment x treatment interaction [F(1,18)=0.348; p=0.562].
We did not find any significant main effect of pretreat-
ment [F(1,18)=0.513; p=0.483], treatment [F(1,18)=0.0645;
p=0.802] and pretreatment x treatment interaction [F(1,18)=
0.696; p=0.415] on BDNF levels in hippocampus. Post-hoc
analysis did not show any significant change in proBDNF and
mature BDNF protein levels in corticosterone or corticosterone
plus cysteamine treated mice as compared to vehicle-treated mice
in frontal cortex and hippocampus (Fig 6). Since we did not find
any change in BDNF protein levels in western blot analysis, we
further examined the BDNF levels by ELISA using frontal cortex
tissue samples from mice treated with vehicle or cysteamine for 3
weeks. We did not find any significant change in BDNF levels
Figure 2. Effects of chronic corticosterone treatment on TrkB protein levels in the frontal cortex. CD-1 male mice were treated with
corticosterone (CORT; 35 ug/ml/day) or vehicle (0.45% hydroxypropyl-b-cyclodextrin) for (A) 3, (B) 5 or (C) 7 weeks. TrkB protein levels were
determined by Western blot analysis. The upper panel shows a representative autoradiogram of TrkB and the lower panel represents the fold change
in optical density values normalized to vehicle-treated controls. b-actin was used as a protein loading control. Values are mean 6 SE (n=5–6 mice per
group). *p,0.05 versus vehicle.
doi:10.1371/journal.pone.0026153.g002
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examined the effects of cysteamine on plasma corticosterone levels.
As we reported earlier [16], we found a significant decrease in
plasma corticosterone levels following corticosterone treatment.
However, cysteamine had no effect on plasma corticosterone levels
in vehicle-treated and corticosterone-treated mice (data not shown).
Cysteamine reverses the chronic corticosterone-induced
anxiety/depression-like phenotype in mice
A number of studies have shown that chronic glucocorticoid
treatment induces anxiety/depression-like behaviors in animals
[2,17]. In the present study, we investigated the effect of
cysteamine on corticosterone treatment-induced anxiety-like
behaviors in an open field (OF), Light/Dark test and Elevated
Plus maze. To determine the effect of cysteamine on depression-
related behavior, mice were tested in the tail suspension test (TST),
a well-established paradigm in which reductions in immobility
reflect antidepressant-like activity.
Fig 7 illustrates the effects of drug treatment on open field
locomotor activity. Mice treated with corticosterone for 7 weeks
showed significant changes in open field activity behavior.
Statistical analysis of the data on time spent in center by two-
way ANOVA with corticosterone/vehicle pretreatment and
cysteamine/vehicle as main effects revealed a significant main
effect of treatment [F(1,30)=5.675; p,0.01] and pretreatment x
treatment interaction [F(1,30)=6.72; p,0.01], but no significant
effect of pretreatment [F(1,30)=2.198; p=0.148]. Subsequent
Post hoc analysis showed that corticosterone-treated mice spent
less time in the center as compared to vehicle-treated mice (Fig 7A;
p,0.05). Interestingly, cysteamine treatment reversed this anxiety-
related behavior (p,0.01 verses corticosterone group in time spent
in the center). There was clear evidence of habituation to the open
field environment in all test groups as indicated by the diminishing
horizontal counts over time (Fig 7B). Two-way ANOVA revealed
a significant main effect of treatment [F(3,177)=9.166; p,0.0001]
and time [F(5,177)=61.49; p,0.0001] without a significant
treatment x time interaction [F(15,177)=0.111; p=1.0]. Howev-
er, post hoc analysis did not show any significant change in
ambulatory counts between treatment groups. In addition, we did
not find any significant change in total ambulatory distance
between treatment groups (Fig 7C). Next, we examined the ratio
of ambulatory distance in center to total distance. Two-
way ANOVA showed a significant main effect of treatment
[F(1,30)=4.512; p,0.01] and pretreatment x treatment interac-
tion [F(1,30)=9.481; p,0.001], but no significant effect on
pretreatment [F(1,30)=1.878; p=0.182]. Post-hoc analysis Cor-
ticosterone-treated mice showed a decrease in the ratio (Fig 7D;
p,0.05) and cysteamine treatment reversed this behavior
Figure 3. Effects of chronic corticosterone treatment on TrkB protein levels in the hippocampus. CD-1 male mice were treated with
corticosterone (CORT; 35 ug/ml/day) or vehicle (0.45% hydroxypropyl-b-cyclodextrin) for (A) 3, (B) 5 or (C) 7 weeks. TrkB protein levels were
determined by Western blot analysis. The upper panel shows a representative autoradiogram of TrkB and the lower panel represents fold change in
optical density values normalized to vehicle-treated controls. b-actin was used as a protein loading control. Values are mean 6 SE (n=5–6 mice per
group). *p,0.05 versus vehicle.
doi:10.1371/journal.pone.0026153.g003
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chronic corticosterone-induced changes in open field activity
behavior in mice.
In Light/Dark Box Assessment, statistical analysis by two-way
ANOVA provided the following results in the time spent in the
brightly lit area, main effect of pretreatment, [F(1,30)=20.97;
p,0.0001]; treatment[F(1,30)=19.25; p,0.0001], and pretreat-
ment x treatment interaction, [F(1,30)=0.0359; p=0.851]]. Data
on the time spent in the dark area showed a significant main
effect of pretreatment [F(1,30)=34.53; p,0.0001] and treatment
[F(1,30)=21.32; p,0.0001], but no significant effect of pretreat-
ment x treatment interaction [F(1,30)=1.143; p=0.2943]. Post
hoc analyses indicated that corticosterone treated mice spent
significantly more time in the dark (Fig 8A; p,0.05) and less
time in the brightly lit zone (Fig 8B; p,0.05) when compared to
vehicle controls. Further, this increased preference for the dark
zone was reversed by cysteamine treatment (p,0.05), again
indicating that cysteamine attenuated the pro-anxiety effects of
corticosterone.
To further validate the potential of cysteamine in reversing the
anxiety-like behavior induced by chronic corticosterone treatment,
we next tested the effects of cysteamine in chronic corticosterone
treated mice in an elevated plus maze test. Two-way ANOVA
provided the following results in the number of entries into the
open arms, main effect of pretreatment [F(1,30)=12.65; p,0.01];
treatment [F(1,30)=8.964; p,0.01], and pretreatment x treat-
ment interaction [F(1,30)=1.185; p=0.286]. We found that
cysteamine reversed the corticosterone-induced reductions in the
number of entries into the open arms (Fig 8C;p,0.05).
Two-way ANOVA on TST showed a a significant main effect
of pretreatment [F(1,24)=6.838; p,0.01] and treatment
[F(1,24)=22.25; p,0.001], but no significant effect on pretreat-
ment x treatment interaction [F(1,24)=00026; p=0.960]. Post-
hoc analyses revealed that chronic corticosterone for 7 weeks did
not result any significant change in immobility score in TST
(Fig 8D). However, cysteamine treatment decreased the duration
of immobility in both vehicle (p,0.05) as well as corticosterone
treated mice (p,0.05).
TrkB is necessary for anxiolytic/antidepressant effects of
cysteamine
We next examined the role of TrkB in mediating the behavioral
effects of cysteamine treatment in mice. In OF, two-way ANOVA
with genotype and treatment as the main effects showed no
significant main effect of genotype [F(1,18)=1.329; p=0.264],
Figure 4. Effects of chronic corticosterone treatment on TrkB
mRNA levels in the frontal cortex and hippocampus. CD-1 male
mice were treated with corticosterone (CORT; 35 ug/ml/day) or vehicle
(0.45% hydroxypropyl-b-cyclodextrin) for 7 weeks. TrkB mRNA levels
were determined by qRT-PCR analysis. The level of TrkB mRNA was
normalized to that of RPS3 RNA in the same sample. Values are
expressed as fold change relative to vehicle-treated mice. Open and
filled bars represent vehicle and corticosterone-treated groups,
respectively. Error bars represent standard Error (SE) of n=4 mice per
group.
doi:10.1371/journal.pone.0026153.g004
Figure 5. Effects of cysteamine in chronic corticosterone-treated mice on TrkB protein levels in the frontal cortex and
hippocampus. CD-1 male mice were treated for 7 weeks with vehicle (0.45% hydroxypropyl-b-cyclodextrin) or corticosterone (CORT; 35 ug/ml) in
the presence or absence of cysteamine (CYS; 150 mg/kg/day) during the last three weeks of corticosterone treatment. TrkB protein levels were
determined in the (A) frontal cortex and (B) hippocampus by Western blot analysis. The upper panel shows a representative autoradiogram of TrkB
and the lower panel represents the fold change in optical density values normalized to vehicle-treated controls. b-Actin was used as a protein loading
control. Values are mean 6 SE (n=5–6 mice per group). *p,0.05 versus vehicle and
#p,0.05 versus CORT.
doi:10.1371/journal.pone.0026153.g005
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[F(1,18)=0.0312; p=0.861]. Post-hoc analysis did not find any
significant difference in the time spent in the center between
vehicle-treated WT and TrkB KO mice (Fig 9A). The lack of
change in open field activity was further tested by examining the
ratio of ambulatory distance in center to total distance. TrkB
knockout mice did not exhibit any significant change in the above
phenotype (data not shown). In addition, we did not find any
significant change in the above measures following cysteamine
treatment indicating that TrkB knockout mice are not responsive
to cysteamine in open field activity.
Since C57BL/6 mice (the strain background for TrkB knockout
mice) are known to respond poor in open filed activity to
antidepressant treatments [18], we next tested the anxiety
phenotype of TrkB knockout mice using two additional behavioral
measures: light/dark test and elevated plus maze. In the light/dark
test, two-way ANOVA provided the following results in the time
spent in brightly lit area, main effect of genotype, [F(1,18)=0.879;
p=0.361], treatment, [F(1,18=5.560; p,0.01]; genotype x
treatment interaction, [F(1,18)=20.45; p,0.001]. Data on the
time spent in the dark area showed a significant effect of genotype
x treatment interaction [F(1,18)=22.54; p,0.001], but no
significant effect of genotype [F(1,18)=2.1; p=0.164] and
treatment [F(1,18)=3.359; p=0.076]. Post hoc analyses indicated
that vehicle treated TrkB knockout mice do not display an
anxious-like phenotype as assessed by the time spent in light and
dark zones (Fig 9B-C). However, we found a significant increase in
time spent in the brightly lit area in control mice following
cysteamine treatment (Fig 9B; p,0.01) that was absent in the
TrkB knockout mice. Similarly, control mice treated with
cysteamine spent less time in the dark zone compared to vehicle
treated control mice (Fig 9C; p,0.01). We next tested the effect of
cysteamine in TrkB knockout mice in an elevated plus maze. Two-
way ANOVA showed significant main effect of genotype
[F(1,18)=7.836; p,0.01] and treatment [F(1,18)=0.5.412;
p,0.01] , but no significant effect of genotype x interaction
[F(1,18)=2.793; p=0.120]. Similar to open field and light/dark
tests, we did not find any significant difference in the elevated plus
maze test between wild-type and TrkB knockout mice (Fig 9D).
Furthermore, while in wild-type mice cysteamine significantly
increased the % of time spent in the open arms (p,0.05),
cysteamine had no effect in mutant mice. Taken together, these
data indicate that TrkB is required for the behavioral effects of
cysteamine in the Light/Dark and EPM.
The role of TrkB in the behavioral effects of cysteamine was
further examined by assessing behavior in TST. Two-way ANOVA
showed significant main effect of genotype [F(1,18)=20.27;
p,0.001] and treatment [F(1,18)=13.85; p,0.01] , but no
significant effect of genotype x interaction [F(1,18)=2.112;
p=0.165]. TrkB knockout mice showed a nonsignificant increase
in immobility relative to wild type mice (Fig 9E; p=0.09).
Moreover, cysteamine significantly decreased the immobility in
control littermates (p,0.05), but TrkB knockout mice did not
respond to cysteamine.
Figure 6. Effects of cysteamine in chronic corticosterone-treated mice on proBDNF and mature BDNF (mBDNF) protein levels in the
frontal cortex and hippocampus. CD-1 male mice were treated for 7 weeks with vehicle (0.45% hydroxypropyl-b-cyclodextrin) or corticosterone
(CORT; 35 ug/ml) in the presence or absence of cysteamine (CYS; 150 mg/kg/day) during the last three weeks of corticosterone treatment. proBDNF
and mBDNF protein levels were determined in the (A) frontal cortex and (B) hippocampus by Western blot analysis. The upper panels shows a
representative autoradiogram of proBDNF and mBDNF and the lower panel represents the fold change in optical density values normalized to
vehicle-treated controls. b-actin was used as a protein loading control. Values are mean 6 SE (n=6 mice per group). (C) BDNF protein levels as
measured by ELISA in frontal cortex samples from mice treated with vehicle or cysteamine for 3 weeks as above. Data represent the fold change in
BDNF protein levels (pg/mg protein) normalized to vehicle-treated controls. Values are mean 6 SE (n=5 mice per group).
doi:10.1371/journal.pone.0026153.g006
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The data from our study provide evidence for the potential of
cysteamine to attenuate corticosterone-induced changes in TrkB
levels as well as anxiety and depression-related behaviors in mice.
Our data also suggest that mice lacking TrkB show reduced
responses to cysteamine treatment in behavior tests.
Our observations of an anxiety-like phenotype in mice following
corticosterone exposure are in agreement with previous findings
[2,17]. A number of studies have suggested that corticosteroids are
involved in the anxiety-like features that are frequently comorbid
with psychiatric disorders such as depression [19]. In addition,
studies have shown that chronic corticosteroid exposure, but not
acute exposure manifests an anxiety-like phenotype in rodents
[2,17]. Our recent study indicated a decrease in serum
corticosterone levels in mice following corticosterone exposure
for 7 weeks [16]. This could be due to the fact that exogenous
corticosterone treatment can flatten the diurnal corticosterone
rhythm rather than result in an absolute increase in circulating
corticosterone levels [20]. Moreover, corticosterone administration
has been shown to inhibit the normal p.m. rise in peripheral
corticosterone levels in rodents (animals were sacrificed between 3
and 4 pm in our study), whereas control animals demonstrate a
normal circadian rhythm of corticosterone [21]. Consistent with
previous report [2], our study indicates that chronic corticosterone
treatment in mice does not result any significant change in
immobility score in TST.
Using a chronic corticosterone-exposed mouse model, we
provide evidence for anxiolytic-like potential of cysteamine, in
OF, Light/dark and EPM tests. It is interesting to note that
vehicle-treated mice were found nonresponsive to cysteamine in
OF and EPM tests. However, when pretreated with corticosterone
for 4 weeks, these mice responded well to cysteamine suggesting
the involvement of two different mechanistic pathways in
cysteamine’s action in pathological vs normal conditions. Although
chronic corticosterone exposure was not associated with significant
change in the immobility score in the TST, cysteamine was
effective in reducing the immobility score in both corticosterone-
treated and vehicle-treated mice.
TrkB plays an important role in stress-induced changes in
neuroplasticity [22], 2010) and TrkB alterations have been linked
to a number of stress related psychiatric disorders [23]. The
expression of full-length TrkB was significantly lower in the PFC
and hippocampus of adult suicide subjects compared with age-
matched healthy controls [24]. To determine whether chronic
corticosterone exposure induces changes in TrkB expression, we
analyzed TrkB mRNA and protein levels in the frontal cortex and
hippocampus, two brains structures involved in the stress response
[25]. We did not find any significant change in TrkB mRNA levels
following corticosterone treatment. This finding suggests that
Figure 7. Effects of cysteamine in chronic corticosterone-treated mice in the Open Field test. CD-1 male mice were treated for 7 weeks
with vehicle (0.45% hydroxypropyl-b-cyclodextrin) or corticosterone (CORT; 35 ug/ml) in the presence or absence of cysteamine (CYS; 150 mg/kg/
day) during the last three weeks of the corticosterone treatment. (A) Mean total of the time-spent in the center for the entire session, (B) the
ambulatory counts for each 5 min period, (C) the total ambulatory distance and (D) the ambulatory distance in the center over total. Values plotted
are mean 6 SEM (n=8–10 per group). Bonferroni’s post hoc test. *p,0.05 versus vehicle and
#p,0.05 versus CORT.
doi:10.1371/journal.pone.0026153.g007
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degradation. Although the mechanism of corticosterone-induced
TrkB protein downregulation is unknown, the role of ubiquitin-
proteasome pathway has been suggested for ligand-induced TrkB
degradation [26]. Further studies are necessary to determine
whether ubiquitin system is involved in chronic corticosterone-
induced TrkB regulation. We found a significant reduction in
TrkB protein levels both in frontal cortex and hippocampus
following chronic corticosterone treatment. Interestingly, TrkB
knockout mice showed a reduced response to cysteamine in the
light/dark, EPM and TST paradigms. This suggests that TrkB
might have a role in mediating anxiolytic/antidepressant actions
of cysteamine.
Recent studies indicate that cysteamine increases brain BDNF
levels in rodents [14-15]. Moreover, acute cysteamine treatment
has been shown to increase hippocampal BDNF levels and reduce
immobility time in FST and TST in mice [27]. However, our
study failed to find any significant difference in BDNF levels in
frontal cortex and hippocampus following cysteamine treatment.
Earlier studies have determined BDNF levels by routine ELISA
methods, which are poor in differentiating pro and mature BDNF
levels. To test the above possibility, we carried out BDNF analysis
by both immunoblot and ELISA methods. However, we could not
find any significant differences in BDNF levels between vehicle-
treated and cysteamine-treated mice. The other possible factor for
the observed discrepancy in BDNF levels between our results and
those of other studies could be the duration of cysteamine
treatment. The duration in our study was 3 weeks whereas the
duration in the other two studies was 7 days. In addition, the time
of animal sacrifice has been shown to play an important role in the
regulation of BDNF expression. BDNF mRNA levels in animals
chronically treated with duloxetine and killed 1 h after the last
administration of the antidepressant were significantly higher than
in those killed at 24 h [28].
In conclusion, the results of this mouse study indicate a potential
for cysteamine to effectively treat corticosterone-related anxiety
and depression symptoms. Our study indicates that cysteamine
treatment improved the anxiety/depression behavior in both
control and corticosteroid-treated animals. The overall hypothesis
of the study was to find whether cysteamine could reverse stress-
induced changes in anxiety/depression-related behavior. As a first
step in this line of research, we have selected corticosterone-
induced mice as a model to test our hypothesis. We need to
perform additional studies using other stress models relevant to
anxiety/depression to validate the potential of cysteamine in stress-
related psychiatric disorders. In addition, it would also be
interesting to determine whether cysteamine could reverse other
corticosterone-induced behaviors that are related to depression or
schizophrenia. Based on the data we have collected to date, it
would be premature to make the statement that cysteamine will be
more effective than the currently available antidepressants.
However, all of the available antidepressant drugs (i.e., both the
newer and older generation agents) have adverse effects (e.g.,
sedation, weight gain, sexual side effects) as well as other
limitations (e.g., drug interactions). Cysteamine might represent
a new class of antidepressants that is not structurally related to any
Figure 8. Effects of cysteamine in chronic corticosterone-treated mice on anxiety-like behaviors as measured in the (A-B) Light/
Dark test, (C) Elevated Plus Maze Maze test and (D) Tail Suspension Test. CD-1 male mice were treated for 7 weeks with vehicle (0.45%
hydroxypropyl-b-cyclodextrin) or corticosterone (CORT; 35 ug/ml) in the presence or absence of cysteamine (CYS; 150 mg/kg/day) during the last
three weeks of the corticosterone treatment. (A) % of the time spent in the dark area, (B) % of the time spent in the lit area; (B) % of the number of
entries in the open arms, and (D) the immobility score (in seconds). Values are mean 6 SE (n=8–9 mice per group). Bonferroni’s post hoc test.
*p,0.05 versus vehicle and
#p,0.05 versus CORT.
doi:10.1371/journal.pone.0026153.g008
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26153Figure 9. Effects of cysteamine in TrkB knockout mice on anxiety-like behaviors as measured in the (A) Open Field test, (B-C) Light/
Dark test, (D) Elevated Plus Maze Maze test and (E) Tail Suspension Test. TrkB knock out (KO) and wild type (WT) male mice were treated for
3 weeks with vehicle (water) or cysteamine (CYS; 150 mg/kg/day). (A) Mean total of the time spent in the center for the entire session, (B) % of the
time-spent in the lit area, (C) % of the time-spent in the dark area, (D) % of the time in open arms, and (E) the immobility score (in seconds). Values are
mean 6 SE (n=6 mice per group). Bonferroni’s post hoc test. *p,0.05 versus vehicle.
doi:10.1371/journal.pone.0026153.g009
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PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e26153of those currently marketed. Therefore it may be of interest to further
evaluate this compound both for antidepressant and anxiolytic
properties. Since cysteamine tolerability has previously been
demonstrated in human subjects (e.g., Huntington Disease patients),
the animal studies described here highlight the potential use of this
compound as a novel therapeutic strategy for glucocorticoid-related
symptoms of psychiatric disorders.
Methods
Ethics Statement
All experiments in the present study were conducted with the
approval of the Medical College of Georgia, Committee on
Animal Use for Research and Veterans Affairs Medical Center
Subcommittee on Animal Use (Protocol # BR10-11-377 dtd. 11/
17/2010).
Animals
CD-1 male mice (25–30 g) were purchased from Charles River
Laboratories, Wilmington, MA, USA. TrkB knockout (TrkB
-/-)
mice were provided by Dr. Barbara Rohrer, Medical University of
South Carolina, Charleston, SC and the colony was maintained in
our animal housing facility at the Georgia Health Sciences
University. The generation of mice lacking the TrkB has been
described previously [29]. Male wild-type (WT) and TrkB
-/- mice
(C57BL/6 strain background) used in a given experiment,
originated from the same breeding series and were matched for
age and weight (age=2–3 months; weight=25–30 g). Animals
were housed 4 mice per cage with water and food available ad
libitum. Mice were maintained on a 12-h light–dark cycle with the
lights on at 0700 hours. All experimental procedures were
performed during the light cycle.
Drug treatment
Fig 1 describes the experimental design used for the drug
treatment. Corticosterone (Sigma, St Louis, MO) was dissolved in
0.45% hydroxypropyl-b-cyclodextrin (Sigma), where as cyste-
amine (Sigma) was dissolved in water. In corticosterone treatment
studies, CD-1 mice were treated for 7 weeks with vehicle or
corticosterone (35 ug/ml equivalent to 5 mg/kg/day) in the
presence or absence of cysteamine (150 mg/kg/day) during the
last three weeks of the corticosterone treatment. In separate set of
experiments, WT as well as TrkB KO mice were administrated
with vehicle or cysteamine (150 mg/kg/day) for 3 weeks. The
vehicle as well as drug solutions were delivered ad libitum in the
drinking water. The dose and duration of corticosterone treatment
was selected based on an earlier study [2] where the above dose
and duration of treatment with corticosterone induced anxiety and
depression-like behaviors in mice. The cysteamine dose was
selected based on earlier studies where this concentration was
found to be non-toxic, but showed neuroprotective effects [14–
15,30]. All animals were monitored for change in body weight and
food intake daily as possible adverse effects of the treatment, and
adjustments were made in the amount of drug depending upon the
fluid consumed and weight of the animals. At the end of the
treatment, the same animal was successively tested in the Open
Field (OF) paradigm, the Light/dark test, the Elevated Plus Maze
test (EPM), the Tail Suspension Test (TST) and then sacrificed for
protein or mRNA analysis.
Western blot analysis
Animals were sacrificed by cervical dislocation, and frontal
cortex and hippocampus samples from vehicle as well as drug-
treated mice were collected according to a mouse brain atlas [31].
The tissue samples were homogenized in ice-cold buffer (10 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 1% Nonidet P-40,
1% sodium deoxycholate) supplemented with protease inhibitor
cocktail (Sigma) containing 104 mM AEBSF, 0.08 mM aprotinin,
2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, and 1.4 mM
E-64. After a 15-min incubation on ice, the extracts were clarified by
centrifugation at 14,000 rpm for 15 min at 4 uCa n ds t o r e da t
270uC. Protein concentrations were determined by the bicincho-
ninic acid method (BCA Protein Assay Kit, Sigma, USA). Equal
amounts of protein were resolved in SDS-polyacrylamide gels and
transferred electrophoretically onto a nitrocellulose membrane (Bio-
Rad). Membranes were blocked for 1 h in TBST (10 mM Tris–HCl,
pH 8.0, 138 mM NaCl, 2.7 mM KCl, and 0.05% Tween-20) and
5% non-fat milk and incubated overnight with the indicated
antibodies. The primary antibodies used were anti-TrkB (1:400;
#4603; Cell Signaling, MA, USA), anti-BDNF (1:250; sc-546; Santa
Cruz Biotech),or anti-b-actin (1:1500; A-5441; Sigma). After washing
with TBST, the membranes were incubated for 1 h with horseradish
peroxidase-conjugated anti-rabbit or anti-mouse anti-sera in TBST
and 3% non-fat milk. The membranes were washed again with
TBST, and proteins were visualized by enhanced chemilumines-
cence. The densitometric values for the proteins of interest were
corrected for protein loading using b-actin. TrkB antibody shows two
bands in the western blots, one at ,98 KDa for truncated TrkB and
the other at ,145 KDa for full-length TrkB receptor. We have
selected the full-length receptor band for our analyses.
RNA isolation and qRT-PCR
Total RNA was isolated from frontal cortex and hippocampal
areas using a commercially available kit (SV RNA Isolation,
Promega, Madison, WI), according to the manufacturer’s instruc-
tions. qRT-PCR was performed on a MastercyclerH ep realplex
2 S
(Eppendorf, Cepheid, Sunnyvale, CA) using a SuperScript III
Platinum SYBR Green One-Step qRT-PCR kit (Invitrogen,
Carlsbad, CA). Primers utilized were as follows: TrkB FL (2257–
2622 bp, Gen Bank accession No: NM_001025074, forward primer
59-GACAATGCACGCAAGGACTT-39; reverse primer 59-AG-
TAGTCGGTGCTGTACACA-39) and housekeeping gene, ribo-
somal protein S3 (RPS3) (284–466 bp, Gen Bank accession No:
NM_012052, forward primer 59-AATGAACCGAAGCACACCA-
TA-39; reverse primer 59-ATCAGAGAGTTGACCGCAGTT-39).
Samples were quantified using serial cDNA dilutions, and data
were normalized to RPS3, which was unaffected by experimental
manipulations [32]. Data were expressed as fold change versus WT
mice. Primer specificity was confirmed by melting curve analysis and
electrophoresis of PCR products on a 2% agarose gel to confirm the
presence of a single band of the predicted size.
Brain-Derived Neurotrophic Factor Immunoassay
Brain-derived neurotrophic factor protein was measured with a
conventional sandwich ELISA using the BDNF Emax Immuno-
Assay System (Promega, Madison, WI, USA) according to the
protocol of the manufacturer.
Behavioral Experiments
All behavioral experiments were conducted in rooms equipped
with white noise generators (San Diego Instruments, San Diego,
CA) set to provide a constant background level of 70 dB and
ambient lighting of approximately 25–30 Lux (lumen/m
2). Test
subjects were handled daily for several minutes (each) for at least
one week prior to experimentation. Animals were transferred (in
their home cages) to the behavioral testing rooms each morning
approximately 30 min before the beginning of experiments. The
behavioral tests were performed in the following order: light/dark
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test. The animals were given two days to recover before the next
behavioral test. All procedures employed during this study were
reviewed and approved by the Medical College of Georgia
Institutional Animal Care and Use Committee and are consistent
with AAALAC guidelines. Measures were taken to minimize pain
or discomfort in accordance with the National Institute of Health
Guide for the Care and Use of Laboratory Animals (NIH
Publications No. 80-23) revised 1996. Significant efforts were also
made to minimize the total number of animals used while
maintaining statistically valid group numbers.
Open Field Activity. Mouse open field activity monitors
(27.9 cm x 27.9 cm, Med Associates St Albans, VT) were used for
these experiments. The following parameters were recorded for
the 30 min test session: horizontal activity (horizontal photobeam
breaks or counts) and vertical activity (vertical photobeam breaks).
Thus, spontaneous locomotor activity, olfactory activity (rearing
and sniffing movements) were assessed. The time spent in the
central and peripheral zones of the apparatus (defined areas
represented approximately 75% and 25% of the total floor area,
respectively) was also recorded as an anxiety-related behavioral
assessment. The first exposure of an animal to the open field can
be used to compare group-related differences in emotionality
induced by exposure to a novel environment. Thigmotaxis (i.e.,
the tendency of rodents to stay in close contact with the walls of
the open field in which they are placed is thought to reflect their
underlying propensity to avoid open, unknown and potentially
dangerous areas [33].
Light-Dark Preference Test. To further assess the effects of
drug treatment on anxiety levels, a Light/Dark Preference Test
(also referred to as light/dark exploration or emergence neophobia
test) was conducted. This test is one of the most commonly-used
rodent models of anxiety [34–35]; and avoidance of the lighted
portion of the chamber reflects elevated anxiety while significantly
reduced time spent in the dark area reflects an anti-anxiety effect
of a test drug. In these experiments, the mouse open field activity
monitors described above were fitted with dark box inserts (which
are opaque to visible light) to cover one-half of the open field area
thus separating the apparatus into two zones of equal area (i.e., a
brightly lit zone and a darkened zone). Desk lamps located above
the activity monitors were used to provide an illumination level of
approximately 1000 lux in the brightly lit zone, whereas the
illumination level in the darkened zone was approximately 5 lux.
The time spent and distance traveled in the light and dark zones of
the apparatus were recorded for the 10 min test session.
Elevated Plus Maze. The elevated plus maze is another
widely used anxiety paradigm based on unconditioned responses
of rodents to a potentially dangerous environment. The maze
exploits the fear of open, and exposed areas (as described above) as
well as the fear of heights [36]. The plus maze comprises two
(opposite) closed and two open arms, each arm located on a
central pole. The combination of height, luminosity and open
space is assumed to induce fear or anxiety in the rodent. The
degree of anxiety is thus assessed by measuring the time spent on
the open and closed arms and the number of entries made into
each arm. The elevated plus maze consisted of two orthogonal
closed (15 cm66c m 630 cm) and open (1 cm66c m 630 cm)
arms forming a cross, with a quadrangular (6 cm66 cm) area
located at the intersection. The maze was placed 50 cm above the
floor and was made of black plastic. Each test lasted 10 min, and
was initiated by placing a mouse on the center facing an open arm.
The behavior of the animal was recorded with a video camera and
later scored by an independent observer blind to treatment. The
following behaviors were scored and compared between groups:
open and closed arm entries (defined as all 4 paws passing the
threshold between the center/intersection portion of the maze and
the beginning a particular arm), time spent and distance traveled
in the closed and open arms as well as in the center area.
Tail suspension test. Animals were tested using the tail
suspension test to assess depressive-like behavior. Each mouse was
suspended by its tail from an aluminum bar and secured with
adhesive tape. Behavior was recorded for 6 min. Observers
blinded to the subject’s treatment group scored video recordings
for time spent struggling or immobile.
Statistical Analyses
Data are expressed as mean6SE. For all experiments one-way
or two-way ANOVA with repeated measure were applied to the
data as appropriate with Bonferroni’s multiple comparison test for
post hoc analysis. Individual comparisons between two groups
were performed with Student’st test. Probability (P) values of less
than 5% were considered significant.
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